Joined Jul 30, 2008
2,107 Blog Posts

Trader’s Guide: CTIC To Take Flight

Cell Therapeutics reports tomorrow.  If we dip, then we could get a good deal.  A lot of traders move this stock, so what’s probably more important than earnings is their drug acceptance dates:

Drug/indication: pixantrone for non-Hodgkin’s lymphoma
FDA acceptance date: Aug. 24
Tentative FDA approval decision date: Dec. 24

Keep those dates in mind and trade around them.  My guess is two weeks before the acceptance date we will start to see more volume return to this bullish flag addict stock.

Ignoring earnings, here’s where we stand:


And of course, I got some help from zMoose, he too has been tracking this bad boy.  It’s always good to get a second opinion whenever you’re in the medical industry…


If you trade CTIC, make sure you keep an eye on DVAX (hat tip PPT crew) which trades in parallel.

Get up to speed on CTIC’s drug, Pixantrone, which is waiting approval.  From their website:

A Potential Treatment for non-Hodgkin’s Lymphoma

Pixantrone (pick-san-trone) (BBR 2778) is a novel DNA major groove binder with an aza-anthracenedione molecular structure that differentiates it from the anthracyclines and other related chemotherapy agents. Pixantrone is under development for the treatment of non-Hodgkin’s lymphoma (NHL) with the goal of demonstrating improved efficacy and better safety than other drugs in this class.

Pixantrone Regulatory Strategy

We are focusing on obtaining pixantrone approval based on the EXTEND (PIX301) phase III clinical trial of pixantrone for patients with relapsed aggressive NHL. Enrollment is complete in this trial, and we have announced that it achieved the primary efficacy endpoint based on a preliminary intent-to-treat efficacy analysis.

In June 2009, we completed submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for pixantrone to treat relapsed or refractory aggressive NHL. We requested priority review by FDA.

The FDA has granted fast track designation for pixantrone in third-line (or more) treatment of relapsed or refractory aggressive NHL.

… sweet.  Anyway, still riding high with AVII.  Cheers!

If you enjoy the content at iBankCoin, please follow us on Twitter


  1. ZMoose12

    Damn skippy my man – thanks for the shout out!

    CTIC staying in that wedge… Wouldn’t mind snagging it around 1.40 if it keeps going 😉

    • 0
    • 0
    • 0 Deem this to be "Fake News"
  2. zstock

    I’m raising my target price GS to 188.4, up from $171

    • 0
    • 0
    • 0 Deem this to be "Fake News"
  3. techFin

    how do you like citi at $1.50??

    • 0
    • 0
    • 0 Deem this to be "Fake News"
  4. zstock

    FOMC and Retail reports—earnings—keep your eyes on the VIX—it’s going to do huge moves ( both ways ) this week.

    • 0
    • 0
    • 0 Deem this to be "Fake News"